Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioject Dissatisfied With Panel Discussion On Jet Injector Guidance

This article was originally published in The Gray Sheet

Executive Summary

Bioject Medical Technologies will be looking for more concrete guidance from FDA than was delivered by the agency's General Hospital and Personal Use Devices Advisory Panel, prior to pursuing approval for specific applications for the Biojector jet injector, the firm says.

You may also be interested in...



FDA Panel Suggests Zero Tolerance For Blood Deposits On Jet Injectors

Manufacturers seeking approval for multiple-use nozzle injectors should demonstrate that no detectable blood or serum residues remain on the device after injection, members of the General Hospital and Personal Use Devices Panel advised Aug. 9

FDA Panel Suggests Zero Tolerance For Blood Deposits On Jet Injectors

Manufacturers seeking approval for multiple-use nozzle injectors should demonstrate that no detectable blood or serum residues remain on the device after injection, members of the General Hospital and Personal Use Devices Panel advised Aug. 9

FDA Jet Injector Policy To Be Addressed At Aug. 9 Advisory Panel

FDA's General Hospital & Personal Use Devices Advisory Panel will convene Aug. 9 in Gaithersburg, Md. to discuss ways to evaluate cross-contamination risk for multiple-use nozzle jet injectors

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel